Pro Medicus Limited

Share Price and News

ASX BIG FOUR - LIVE SNAPSHOT

SELL

Whitehaven Coal

(ASX:WHC)

Paul Flynn
01/03/2026
$8.7m
BUY

Elixir Energy

(ASX:EXR)

Featured
SELL

Aspen Group

(ASX:APZ)

David Dixon
03/03/2026
$11.4m
BUY

Lovisa

(ASX:LOV)

Brett Blundy
04/03/2026
$6.8m
Company Overview

About Pro Medicus (ASX:PME)

Pro Medicus is an Australian business specialising in medical imaging technology. Founded and based in Melbourne, Victoria, in 1983, its Visage 7 software enables  hospitals and diagnostic imaging providers to efficiently manage and interpret large volumes of medical images. The platform is known for its speed, scalability, and native cloud architecture. The company has a strong presence in North America and is expanding its activities in Europe and other international markets. Its SaaS business model delivers high-margins and recurring revenue. These factors have meant the company has not had to raise capital and its share price has kept expanding and expanding as it continues to roll out into the US. Moreover,  The company’s software requires minimum capex to be installed or training for clients to use.

Pro Medicus Company History

The company was founded in Melbourne in 1983 by Dr Sam Hupert and Anthony Hall. Having recently graduated from medical school, the pair saw potential for the use of computers in medicine, even when computers were more complicated. Initially, it gained a foothold in healthcare IT through medical practice management software and later through helping patients receive diagnostic results faster. In 2000 it listed and managed to survive the dot com burst. It expanded overseas, including into North America through a deal with Agfa. In 2009, the company bought Visage Imaging, a German and U.S.-based imaging software firm that was then owned by Mercury Systems. It paid just US$3.5m. Following the acquisition, the company launched Visage 7, which became central to its product offerings and positioned Pro Medicus as a leader in medical imaging. Since then, client numbers have increased through long-term contracts with major health networks and leading academic hospitals in the US. 2014 was a key year when it unveiled a six-year deal worth $20m with a large US health network. The deals have kept flowing since then, but that first one was major because PME won out of nearly 30 companies (including majors like GE, Phillips and Siemens). The rest is history. In FY24, Pro Medicus generated $161.5m in revenue and an $82.8m profit, representing a near 50% margin. Its biggest deal in that year was a 10-year US$140m deal with Baylor Scott & White.

Get Our Full ASX Stock Analysis Report

Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.

Forward View

Future Outlook of Pro Medicus (ASX: PME)

Pro Medicus is well-positioned amid an ever-growing market. Despite having A$624m in contracts over 5 years assuming current contracts up for renewal are renewed, the company claims it has only penetrated 7% of the market and that it is growing by 3.5% per year. Moreover, it claims that it could benefit from adopting AI in its software, and expanding it to other health services using medical imaging, such as cardiology. The key risks are competition, key personnel risk and macroeconomic risks. That said, as advances in medical imaging continue, the data required keeps expanding.  For example, an optoacoustic breast ultrasound can take up more than 10 GB of computer storage. This means downloading images, and in turn viewing them, can take a while and waiting reduces radiologists’ productivity. And in a post-COVID world, with even doctors now working from home, you don’t want you images just sitting on one computer in an office somewhere.

Our Assessment

Is PME a Good Stock to Buy?

Pro Medicus has consistently delivered strong returns, making it one of the most closely watched technology stocks on the ASX. Its financial performance is supported by long-term contracts, high margins, and a recurring revenue model tied to imaging volumes from some of the top hospitals globally. That said, its valuation is demanding, trading at a high price-to-earnings multiple relative to the broader market. This suggests the market has priced in a significant portion of future growth. Investors should weigh this premium against the company’s strong fundamentals, debt-free balance sheet, and impressive growth pipeline. For growth-focused investors comfortable with tech-sector volatility, PME remains a quality business with strong fundamentals and global appeal.

Our Stock Analysis

Orcoda (ASX:ODA) lands A$8m-a-year Wagner deal that finally puts Contractor360 to work

Orcoda (ASX:ODA) has signed a multi-year A$8m per annum workforce logistics and facilities management contract…

Pro Medicus (ASX:PME) writes a A$20m cheque into Echo IQ

Pro Medicus (ASX:PME) commits up to A$20m to Echo IQ via secured convertible notes and…

Activeport (ASX:ATV) bolts a 6% revenue cut onto Australia’s GPU rush

Activeport Group (ASX:ATV) launches an AI Gateway with FirstWave, earning 6% of GPU consumption revenue…

Micron (NASDAQ:MU) Surges 13% on Monster Q3, But the Cycle Risk Hasn’t Gone Away

Micron Surges as 84% Margins Keep the AI Memory Trade Alive Micron is currently showing…

Is the AI Bubble Bursting? Why Nvidia, Micron and Chip Stocks Are Crashing

KEY POINTS A global chip sell-off dragged the US Nasdaq down 2.21% overnight, with…

Cerebras (NSDQ:CBRS) just booked a US$20 billion OpenAI deal

Cerebras Systems (NSDQ:CBRS) posted 92% core revenue growth in Q1 2026 alongside a US$20 billion…
Faq

Frequently Asked Questions

What does Pro Medicus do?
Pro Medicus provides advanced radiology imaging software through its flagship Visage 7 platform, used by hospitals and diagnostic groups to manage and analyse medical images.
Yes. Pro Medicus reported strong growth in FY24, with double-digit increases in both revenue and profit. The company continues to sign new contracts and expand its client base.
Yes. The company pays fully franked dividends and has increased payouts in line with earnings growth while retaining sufficient cash for reinvestment.
PME trades at a high valuation, reflecting strong investor confidence. While some view it as expensive, others believe its consistent growth and long-term contracts justify the premium.
Key risks include high valuation, dependence on the U.S. market, potential changes in healthcare spending, and competition from other imaging technology providers.

Stay Sharp on the ASX

Weekly research. Independent analysis. No noise.

Free forever · Unsubscribe anytime

© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here